A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered PWT33597 Mesylate in Subjects With Advanced Malignancies
This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical effects of orally administered PWT33597 mesylate in subjects with advanced malignancies.
100 Clinical Results associated with Pathway Therapeutics, Inc.
0 Patents (Medical) associated with Pathway Therapeutics, Inc.
100 Deals associated with Pathway Therapeutics, Inc.
100 Translational Medicine associated with Pathway Therapeutics, Inc.